Pillars of growth
Heavy bet for R&D
as a future
growth engine
Heavy bet on R&D
as a future
growth engine
Biosimilars
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.
Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
CDMO
High production capacity with four the manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
743.5 Mn€
Operatig revenuein 2025
473.9 Mn€
Specialty Pharmaceutical business Sales in 2025 (+2% vs 2023)
+60
countries
LMWH presence through strategic alliances with international partners
37.8 Mn€
R&D expenses in 2025 (+47% vs 2024)
269.5 Mn€
CDMO Sales in 2025
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Last news on Rovi
Deprecated: Array and string offset access syntax with curly braces is deprecated in /var/www/vhosts/rovi.es/httpdocs/sites/all/modules/views_php/plugins/views/views_php_handler_field.inc on line 217
Last annual report
Sustainability report 2025
Last regular
public information
Presentation 2025
